Krystal Biotech IncKRYS
ASignal's systematic analysis rates KRYS as Bullish.
Reflects the latest available analysis · analyzed Aug 30, 2026
The case on KRYS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (24.1%) and earnings growth (38.8%)
- Exceptional gross margin (94.64%) indicating pricing power
- High return on equity (20.12%) reflecting capital efficiency
- Low debt-to-equity ratio (0.01x) signaling strong financial health
- Positive MACD histogram with MACD above signal line
- Price above 20-day and 50-day moving averages
- High P/E ratio (44.83x) and forward P/E (37.40x) relative to market
- Elevated EV/EBITDA (48.00x) suggesting valuation risk
- No Reddit mentions, indicating low retail investor interest
- RSI at 62, approaching overbought territory
See the full verdict on KRYS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes KRYS
Most investors never get a second opinion, let alone several. ASignal runs KRYS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.